Rapport Therapeutics, Inc. Common Stock

NASDAQ:RAPP

Biotechnology

Healthcare
$23.40 +0.05%

+$0.02 today

Market cap
$1.12B
Beta
0.98
P/E (TTM)
-16.2
EPS (TTM)
-$2.27
52W Low $10.51High $42.27

Volume 0.73M

Average 0.33M

RAPP Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $19.86M (cash outflow) fell 17.5% year over year, behind the +34.6% change in trailing-twelve-month net income. Sequentially, it fell 41.2% from the prior quarter. Over 3 fiscal years it compounded at +118.7% a year.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 10 analysts of -$165.1M (+48.1%) for the fiscal year ending Dec 2026, a step up from the +42.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$19.86M-41.2% QoQ
Last fiscal yearDec 2025
-$111.48M+42.4% YoY
LTMMar 2026
-$107.28M+34.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.5%+70.2%+87.7 pp
1 year+42.4%+48.1%+5.7 pp
3-year CAGR+118.7%+29.5%-89.2 pp
5-year CAGR+10.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(111.48M) USD
Year-over-year change
-42.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How RAPP compares with its peers on the latest reported figures

  • RAPP's LTM Mar 2026 net income of $107.28M is the 6th largest of the 10 companies compared; the peer median is $74.31M.
  • Its year-over-year change of +34.6% is the 3rd highest of 9, against a peer median of +17.4%.
  • Net income amounts to 536.4% of revenue for RAPP, versus a peer median of 29.2%.
RAPP Competitors Peer median
Net Income for RAPP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$384.12M +72.9%—33.7%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$359.43M +31.6%+12.3%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$222.39M -13.8%+21.9%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$199.48M +146.3%+75.1%—
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$191.64M -22.4%-0.7%24.7%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$107.28M +34.6%+118.7%536.4%
ANROAlto Neuroscience, Inc.LTM Mar 2026$74.31M +17.6%+31.7%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$58.44M +17.3%+35.2%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$39.17M —+20.7%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$19.58M -41.2%+3.2%—
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding RAPP) $74.31M+17.4%+21.3%29.2%

Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(10.65M)(34.79M)(78.31M)(111.48M)
Depreciation & Amortization16.36K112K839K1.02M
Deferred Income Tax0000
Stock-Based Compensation609.82K3.53M10.24M18.86M
Change in Working Capital1.49M2.65M(2.42M)3.5M
Accounts Receivables0000
Inventory0000
Accounts Payables0856K(346K)2.22M
Other Working Capital1.49M1.8M(2.07M)1.29M
Other Non-Cash Items5.3M1.32M4.82M636K
Operating Cash Flow(3.24M)(27.18M)(64.83M)(87.47M)
Capital Expenditures(284K)(1.64M)(2.41M)(616K)
Acquisitions (Net)0000
Purchases of Investments0(77.22M)(380.74M)(354.78M)
Sales of Investments00209.8M167.93M
Other Investing Activities(5M)03.21M0
Investing Cash Flow(5.28M)(78.86M)(170.14M)(187.47M)
Debt Repayment7.9M000
Common Stock Issued31.79M54K157.71M270.79M
Common Stock Repurchased0(4K)0(1K)
Dividends Paid0000
Other Financing Activities0(134K)7K0
Financing Cash Flow39.69M145.14M221.63M270.79M
Effect of Forex Changes0000
Net Change in Cash31.16M39.1M(13.34M)(4.16M)
Free Cash Flow(3.53M)(28.82M)(67.23M)(88.09M)

Rapport Therapeutics, Inc. Common Stock

NASDAQ:RAPP

Intrinsic Alpha fair value

Locked

Current Price

$23.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.